Loading organizations...
Loading organizations...
Sonexa Therapeutics is a technology company.
Sonexa Therapeutics, Inc. is a biotechnology company focused on the development of novel drug therapies for Alzheimer's disease and related neurological disorders. The firm strategically licenses and advances experimental compounds, targeting conditions where significant unmet medical needs persist. Their scientific approach centers on bringing innovative therapeutic candidates through clinical development to address these complex diseases.
Details regarding the company's founding are not readily available in public summaries. Based in San Diego, Sonexa Therapeutics emerged with an emphasis on advancing a pipeline of experimental drugs. The company secured initial financing to propel its therapeutic candidates towards human trials, signaling a commitment to clinical validation for its novel treatments.
Ultimately, Sonexa Therapeutics aims to serve patients afflicted with Alzheimer's and similar debilitating neurological conditions, offering new hope through advanced pharmacological interventions. The company's long-term vision is to successfully develop and commercialize these specialized biotechnology drugs, significantly improving treatment paradigms and patient outcomes in neurodegenerative care.
Sonexa Therapeutics has raised $30.0M across 1 funding round.
Sonexa Therapeutics has raised $30.0M in total across 1 funding round.
Sonexa Therapeutics has raised $30.0M in total across 1 funding round.
Sonexa Therapeutics's investors include Domain Associates, Santé Ventures.
Sonexa Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for Alzheimer's disease and related disorders.[2][3][5] Based in San Diego, it focuses on novel drug treatments, with a drug pipeline, technology platform, three clinical trials, and one associated literature reference.[1] The company raised $30 million in Series A financing in January 2008 to license and advance a novel compound (with worldwide exclusive rights except Japan and certain Asian countries), funding U.S. human trials starting February 2008; it serves patients with Alzheimer's by addressing unmet needs in disease treatment.[4]
Sonexa Therapeutics emerged around 2007-2008, founded with backing from Domain Associates, a life sciences-focused venture capital firm.[4] Founding CEO Eckard Weber, M.D., a Domain Associates partner and serial founder of over a dozen biopharmaceutical companies, serves as Chairman.[4] The leadership includes President and CMO Sharon Rogers, Ph.D., who contributed to developing Aricept, the leading Alzheimer's drug at the time.[4] Key investors comprised Domain Associates, Scale Venture Partners (via Managing Director Lou Bock), Alta Partners (Robert Alexander, Ph.D.), AgeChem Venture Fund, and MC Life Science Ventures.[4] A pivotal moment was securing the Series A to license the Alzheimer's compound from a Japanese pharmaceutical company, enabling rapid clinical progression.[4]
Sonexa rode the early 2000s wave of Alzheimer's research intensification, amid growing recognition of the disease's prevalence and limitations of existing treatments like Aricept.[4] Timing aligned with venture interest in biopharma, particularly post-2000s biotech boom, as aging populations drove demand for neurodegeneration therapies.[2][3] Market forces favoring Sonexa included Japan's pharma innovation outsourcing and U.S. clinical trial infrastructure, positioning it to influence Alzheimer's drug development ecosystems through validated leadership and early-stage momentum.[1][4]
Sonexa is poised to advance its lead Alzheimer's candidate through clinical stages, leveraging its 2008 funding and trial starts amid evolving neurodegeneration pipelines.[1][4] Trends like AI-driven drug discovery and amyloid/tau-targeting advances could accelerate progress, though competition from later entrants (e.g., post-2010 approvals) poses risks. Its influence may grow via potential partnerships or acquisitions, building on founder expertise to shape Alzheimer's therapeutics—echoing its origins as a targeted biotech challenger.[2][3][4]
Sonexa Therapeutics has raised $30.0M across 1 funding round. Most recently, it raised $30.0M Series A in January 2008.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2008 | $30.0M Series A | Domain Associates, Santé Ventures |